Where Innovation Is Moving The Advanced Therapies Supply Chain: A Q&A With Alison Pritchard

Advanced therapies are pushing supply chains into unfamiliar territory, where a single shipment can represent a patient’s only dose. In this Q&A, Alison Pritchard shares how innovation is reshaping logistics models to meet that reality. The conversation highlights a shift from linear, product-focused supply chains to patient-centric networks designed around visibility, control, and risk mitigation. Topics include the growing complexity of cold chain requirements, the need for end-to-end data and chain-of-custody integrity, and how decentralized manufacturing changes planning and execution. Pritchard also discusses why collaboration across sponsors, manufacturers, and logistics partners is becoming essential as therapies scale globally. Rather than chasing speed alone, the focus is on resilience—anticipating disruptions, building flexibility, and aligning operations with evolving regulatory expectations. Readers will gain a practical view of where advanced therapy supply chains are headed and what capabilities will matter most in the years ahead.